Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
This study has been terminated.
(Study terminated due to low accrual.)
Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborator:
Genentech
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT01015300
First received: November 16, 2009
Last updated: May 9, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | April 2012 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |